Before the revolution, the administration of drug-related affairs was under the jurisdiction of the Ministry of Health, and the first law related to this field was passed in 1955, titled “The Law on Medical and Pharmaceutical Regulations and Food and Beverages.” This law underwent amendments in 1967. Since then, no significant legislation has been enacted in this area, and given the changes in the industry over the past 50 years, there has long been a need for revision. One of the key demands of industry stakeholders, particularly the private sector, is regulatory reform. I recently had the opportunity to share my thoughts, based on two decades of experience in this industry, with some of the key players in this field.

In summary, my suggestion is to update the law based on a developmental perspective, taking into account the opinions of stakeholders, especially the private sector, and more importantly, patient representatives from various support associations. Clearly, the abolition of Article 20 Commission, whose subjective approach has hindered the industry’s ability to pursue developmental planning, is also necessary.